Biodesix, Inc. (BDSX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 46 | 55 | 38 | 49 | 71 | 88 | 103 | 112 |
| Operating profit | $m | -28 | -21 | ||||||
| Net profit | $m | -31 | -43 | -65 | -52 | -43 | -35 | -28 | -20 |
| EPS reported | $ | -4.67 | -3.17 | ||||||
| Operating cashflow per share | $ | -3.08 | -1.93 | ||||||
| Capex per share | $ | 0.05 | 0.06 | ||||||
| FCF per share | $ | -3.14 | -1.98 | ||||||
| Free cash flow | $m | -24 | -20 | ||||||
| Net debt | $m | 28 | 17 | ||||||
| Book value equity | $m | -2 | 9 | ||||||
| Book value per share | $ | -0.33 | 0.89 | ||||||
| Number of shares | m | 7.55 | 10.3 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -20.83 | 5.62 | ||||||
| P/S LTM | x | 0.58 | 0.50 | ||||||
| P/FCF LTM | x | -2.17 | -2.52 | ||||||
| EV/EBITDA LTM | x | -4.79 | -7.37 | ||||||
| EV/Sales LTM | x | 1.19 | 2.48 | ||||||
| Earnings Yield LTM | % | -68.68% | -10.30% | ||||||
| FCF Yield | % | -46.11% | -39.73% | ||||||
| Quality | |||||||||
| ROE | % | +1430.6% | -788.19% | ||||||
| ROIC | % | -38.88% | -25.22% | ||||||
| Operating margin | % | -31.37% | -20.01% | ||||||
| Gross margin | % | +81.11% | +82.50% | ||||||
| FCF/Sales | % | -26.75% | -19.82% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +24.08% | +44.33% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.32 | -0.28 | ||||||
| Net Debt/EBITDA | x | -2.45 | -2.93 | ||||||
| EBIT/Net interest | x | -3.60 | -2.54 | ||||||
| Net debt/market cap | % | +92.41% | +21.97% | ||||||
| Net debt/Equity | x | -11.55 | 1.84 | ||||||
| Gross debt/equity | x | -29.56 | 7.85 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free